Find out more about the availability of cancer medicines in
- Enter in the search engine or select from the list
Select the type of cancer and see a full compilation of pharmaceutical therapies authorized by European Medicines Agency (EMA) in last 15 years and recommended by the European Society for Medical Oncology (or enter the medicine and check if it is reimbursed).
- Download or print out the list
Medicines increasing the chances of your successful recovery might be on the list.
- Consult the list with your doctor
Ask your doctor to verify the possible medicines and indicate the once which can be the most effective in your case. The list may also include non-reimbursed therapies. In such a situation contact us - we will help you find a solution.
non-Hodgkin lymphoma
How to read the list?Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.
-
TemsirolimusTemsirolimus is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).No reimbursementThe drug in this indication is not refundedESMOSubstance is recommended by ESMO.
-
IdelalisibProdukt Idelalisib jest wskazany w monoterapii u dorosłych pacjentów z chłoniakiem grudkowym (ang. Follicular Lymphoma, FL), który jest oporny na dwie wcześniej zastosowane linie leczenia.No reimbursementThe drug in this indication is not refundedESMOSubstance is recommended by ESMO.
-
Brentuximab vedotinBrentuximab Vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). Brentuximab Vedotin is indicated for the treatment of adult patients with relapsed or refractory sALCL. Brentuximab Vedotin is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.Reimbursement with restrictionsThe drug in this indication is reimbursed for a narrower group of patients than is apparent from the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
Pixantrone dimaleatePixantrone Dimaleate is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
IbrutinibIbrutinib as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
BortezomibBortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
ObinutuzumabObinutuzumab in combination with chemotherapy, followed by Obinutuzumab maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced FL. Obinutuzumab in combination with bendamustine followed by Obinutuzumab maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.
-
LenalidomideLenalidomide in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). Lenalidomide as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Full reimbursementThe drug in this indication is refunded in accordance with the ESMO guidelinesESMOSubstance is recommended by ESMO.